Regarding the PD-1–PD-L1 axis, the first anti-PD-1 Ab, pembrolizumab, developed following the findings of Nobel Prize winner Tasuku Honjo, was approved by the FDA in 2014 to treat advanced melanoma. This evidence concerns the gene PDCD1 and melanoma.